Boston Scientific Corporation (NYSE:BSX) Receives $92.29 Consensus Target Price from Analysts

Shares of Boston Scientific Corporation (NYSE:BSX) have been given an average rating of “Moderate Buy” by the twenty-eight brokerages that are covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $86.7917.

BSX has been the subject of several recent research reports. Mizuho dropped their price objective on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. Bank of America reduced their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Needham & Company LLC reiterated a “buy” rating and set a $77.00 price objective on shares of Boston Scientific in a research note on Monday, May 18th. Oppenheimer set a $90.00 target price on shares of Boston Scientific in a report on Thursday, April 23rd. Finally, Leerink Partners dropped their target price on shares of Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a report on Thursday, May 28th.

Boston Scientific Stock Performance

NYSE:BSX opened at $47.79 on Thursday. Boston Scientific has a 1-year low of $47.17 and a 1-year high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The firm has a 50 day simple moving average of $58.92 and a 200-day simple moving average of $77.28. The firm has a market cap of $71.03 billion, a PE ratio of 19.99, a P/E/G ratio of 0.89 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the prior year, the business posted $0.75 earnings per share. Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities analysts expect that Boston Scientific will post 3.37 EPS for the current year.

Boston Scientific announced that its board has authorized a share buyback program on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling

In other news, Director Cheryl Pegus acquired 1,770 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average price of $56.49 per share, with a total value of $99,987.30. Following the acquisition, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig bought 3,580 shares of the stock in a transaction on Wednesday, May 20th. The shares were bought at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the purchase, the director owned 25,359 shares in the company, valued at $1,437,348.12. This trade represents a 16.44% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought a total of 9,800 shares of company stock valued at $554,012 in the last quarter. Company insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Boston Scientific by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after purchasing an additional 1,436,550 shares in the last quarter. State Street Corp boosted its holdings in shares of Boston Scientific by 1.4% during the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after purchasing an additional 920,495 shares during the period. Capital World Investors boosted its holdings in shares of Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after purchasing an additional 502,627 shares during the period. Norges Bank acquired a new stake in shares of Boston Scientific during the fourth quarter worth approximately $2,199,395,000. Finally, Morgan Stanley raised its position in Boston Scientific by 10.8% during the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock valued at $2,189,289,000 after acquiring an additional 2,246,308 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.